Under terms of the agreement, PhytoMedical will continue to undertake its research at ISURF for development of the Company's novel, synthesized type A-1 'polyphenolic' compounds - an entirely new, innovative class of compounds derived from cinnamon, shown in published human and pre-clinical animal studies to favorably effect type-2 diabetes without side effects.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.